Julie Haugaard Vandtved, Andreas Kiesbye Øvlisen, Joachim Baech, Ulla Møller Weinrich, Marianne Tang Severinsen, Eva Futtrup Maksten, Lasse Hjort Jakobsen, Ingrid Glimelius, Peter Kamper, Martin Hutchings, Lena Specht, Rasmus Dahl-Sørensen, Jacob Haaber Christensen, Tarec C El-Galaly
Late toxicities can impact survivorship in patients with classical Hodgkin lymphoma (cHL) with pulmonary toxicity after bleomycin-containing chemotherapy being a concern. The incidence of pulmonary diseases was examined in this Danish population-based study. A total of 1474 adult patients with cHL treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or BEACOPP (bleomycin, vincristine, etoposide, doxorubicin, cyclophosphamide, procarbazine and prednisone) between 2000 and 2018 were included along with 7370 age- and sex-matched comparators from the background population...
April 29, 2024: British Journal of Haematology